| Market Cap | 19.27M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -17.76M | Forward P/E | -2.11 | EPS next Y | - | 50D Avg Chg | -19.00% |
| Sales | 356k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -39.00% |
| Dividend | N/A | Price/Book | 6.70 | EPS next 5Y | - | 52W High Chg | -80.00% |
| Recommedations | 1.00 | Quick Ratio | 0.24 | Shares Outstanding | 2.60M | 52W Low Chg | 9.00% |
| Insider Own | 10.07% | ROA | -495.64% | Shares Float | 124.91K | Beta | 0.98 |
| Inst Own | 52.30% | ROE | - | Shares Shorted/Prior | 55.03K/93.08K | Price | 0.29 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 207,593 | Target Price | - |
| Oper. Margin | -2,466.38% | Earnings Date | Nov 11 | Volume | 40,827 | Change | 0.27% |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zauderer Maurice | President and CEO President and CEO | Oct 03 | Buy | 0.97 | 510,000 | 494,700 | 22,116 | 10/05/23 |
| FRIEDBERG ALBERT | Director Director | Oct 03 | Buy | 1.0 | 3,000,000 | 3,000,000 | 4,747,794 | 10/05/23 |
| Frieberg Jacob B. | Director Director | Jan 27 | Buy | 1.11 | 90,090 | 100,000 | 94,510 | 01/31/22 |
| FRIEDBERG ALBERT | Director Director | Jan 27 | Buy | 1.11 | 3,603,602 | 3,999,998 | 11,580,436 | 01/31/22 |
| Zauderer Maurice | President and CEO President and CEO | Jan 27 | Buy | 1.11 | 1,801,801 | 1,999,999 | 2,899,554 | 01/31/22 |